Veraxa Biotech AG - Post de-SPAC
No enriched coverage for $VRXA in the last 7 days.
Veraxa Biotech AG (VRXA) named Raju Willener as its new Chief Financial Officer. Willener brings over 30 years of financial leadership experience in biopharmaceuticals. CEO Christoph Antz stated Willener's expertise will support capital strategy and shareholder value creation.
VERAXA Biotech AG (NASDAQ: VRXA) appointed Raju Willener as Chief Financial Officer, effective immediately. Willener brings over 30 years of experience in global capital markets and corporate finance. The company develops antibody-based cancer therapies and is advancing its BiTAC technology platform.
Baumann Oliver Rolf purchased 50,000 indirectly-held shares of Veraxa Biotech AG - Post de-SPAC (VRXA) at $1.50 on 2026-08-27.
Recent VRXA coverage spans financial news, corporate actions and insider activity.
In the last 30 days, VRXA insiders filed 2 SEC Form 4 transactions — 2 purchases ($83K) and no sales. The most active reporter was Baumann Oliver Rolf with 1 filing.
New CFO may influence capital strategy and execution.
New CFO may influence capital strategy and financing activities.
Baumann Oliver Rolf purchased 50,000 indirectly-held shares of Veraxa Biotech AG - Post de-SPAC (VRXA) at $1.50 on 2026-08-27.
Small insider purchase may signal confidence but size is negligible.
The update strengthens VERAXA’s IP moat around its BiTAC-TCE and BiTAC-ADC platforms, potentially improving perceived defensibility for investors.
AlphAI scores every news story that mentions VRXA with an AI model for sentiment and relevance, and aggregates insider trades from Veraxa Biotech AG - Post de-SPAC's SEC EDGAR Form 4 filings. Figures refresh continuously.
Veraxa Biotech AG (VRXA) named Raju Willener as its new Chief Financial Officer. Willener brings over 30 years of financial leadership experience in biopharmaceuticals. CEO Christoph Antz stated Willener's expertise will support capital strategy and shareholder value creation.
1 min readVERAXA Biotech AG (NASDAQ: VRXA) appointed Raju Willener as Chief Financial Officer, effective immediately. Willener brings over 30 years of experience in global capital markets and corporate finance. The company develops antibody-based cancer therapies and is advancing its BiTAC technology platform.
1 min readBaumann Oliver Rolf purchased 50,000 indirectly-held shares of Veraxa Biotech AG - Post de-SPAC (VRXA) at $1.50 on 2026-08-27.
1 min readAntz Christoph Rudiger (Chief Executive Officer) purchased 5,000 shares of Veraxa Biotech AG - Post de-SPAC (VRXA) at $1.53 on 2026-08-27.
1 min readVERAXA Biotech AG (NASDAQ: VRXA) said it filed first BiTAC-related patent applications in H1 2026 covering its BiTAC-TCE and BiTAC-ADC platforms, including composition of matter and payload technologies. It also reported granted auxiliary patents clearing opposition. VERAXA has 50+ granted patents in 14 countries across 26 families, targeting protection through at least 2047.
4 min readVERAXA Biotech AG (NASDAQ: VRXA) said shareholders approved all proposals at an extraordinary general meeting. The vote passed with more than 99.94% approval, with 102,102,301 voting shares represented, or 72.20% of total share capital. Resolutions add conditional share capital, a capital band through Dec. 31, 2030, and expand the board from five to seven to support financing and strategic options.
3 min readVERAXA Biotech AG (NASDAQ: VRXA) appointed Christoph Erkel, Ph.D. as Chief Scientific Officer effective immediately. Erkel, previously VP of R&D, will lead development of the company’s BiTAC platform technologies for solid-tumor cancer therapies. He replaces Rick Austin, Ph.D., who will depart after a transition. The release cites Erkel’s 20 years in antibody therapeutics.
2 min readVERAXA Biotech AG (NASDAQ: VRXA) said it will launch an AI-enabled drug discovery collaboration with Ardigen S.A. to support VERAXA’s BiTAC pipeline of T cell engagers and future BiTAC-ADCs. The work will focus on AI tools to select synergistic cancer target pairs using dual-target “AND-gate” activation, aiming to improve oncology development decisions.
3 min readVERAXA Biotech AG (NASDAQ: VRXA) appointed Carl von Halem as interim CFO, replacing Torsten Bürgermeister. The company said it is in the final stages of talks with a successor and will update the market later. The release cites von Halem’s prior CFO role at Xlife Sciences and other life-sciences finance experience.
2 min readBiotech gainers included SL Science (SLBT), up 34.61% to $5.99 after Nasdaq trading began June 15; Chemomab (CMMB), up 33.53% to $2.27 as Phase 3 preparations for Nebokitug in primary sclerosing cholangitis continue; Propanc (PPCB), up 22.92% to $1.77 after a $500k buyback authorization. Also: VERAXA (VRXA) +18.26% to $2.04 with ATUM support; Tectonic (TECX) +15.85% to $37.93 ahead of Phase 2/1 catalysts; Aura (AURA) +15.01% to $7.74 ahead of bel-sar data; SELLAS (SLS) +12.89% to $14.98 with REG
7 min read
